(Q33939795)

English

Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

0 references

Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Wenjin Yin

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Yiwei Jiang

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Zhenzhou Shen

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Zhimin Shao

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Jinsong Lu

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

language of work or name

0 references

publication date

9 June 2011

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

e21030

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

copyright license

Creative Commons Attribution 4.0 International

9 June 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Cancer statistics, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111470

28 July 2018

Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111470

28 July 2018

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111470

28 July 2018

Jumping higher: is it still possible? The ALTTO trial challenge

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111470

28 July 2018

Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111470

28 July 2018

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111470

28 July 2018

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111470

28 July 2018

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111470

28 July 2018

Measuring inconsistency in meta-analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111470

28 July 2018

Determinants and prognoses of locoregional and distant progression in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111470

28 July 2018

Trastuzumab: hopes and realities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111470

28 July 2018

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111470

28 July 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111470

28 July 2018

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111470

28 July 2018

The natural history of breast cancer patients with brain metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111470

28 July 2018

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0021030

21 January 2018

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0021030

21 January 2018

Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0021030

21 January 2018

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0021030

21 January 2018

Central nervous system metastasis from breast carcinoma. Autopsy study.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0021030

21 January 2018

Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0021030

21 January 2018

Use of intrathecal trastuzumab in a patient with carcinomatous meningitis.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0021030

21 January 2018

Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0021030

21 January 2018

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0021030

21 January 2018

Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111470

29 October 2018

Sequential or Concurrent Administration of Trastuzumab in Early Breast Cancer? Too Early to Judge

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0021030

21 January 2018

Breast cancer: metastatic patterns and their prognosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21695277

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Defining prognosis for women with breast cancer and CNS metastases by HER2 status

1 reference

https://pubmed.ncbi.nlm.nih.gov/21695277

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0021030

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

2011PLoSO...621030Y

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33939795&oldid=1966942436"